Provectus Biopharmaceuticals, Inc.
PVCT- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000315545
No open-market purchases or sales by Provectus Biopharmaceuticals, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $8.97K in total; no superinvestor holds it.
Holders of 5% or more of PVCT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Provectus Biopharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Pershing Edward | 13D/A | 10.56%49.3M shares | – | Dec 1, 20251 filing | Dec 1, 2025 | SEC |
| Rodrigues Dominic | 13D | 5.67%25.2M shares | New | Dec 8, 20251 filing | Dec 8, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Provectus Biopharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Dec 8, 20259:53 AM ET | Rodrigues Dominic | 13D | 5.67%25.2M shares | New | Dec 2, 2025 | SEC |
| Dec 1, 20259:52 PM ET | Pershing Edward | 13D/A | 10.56%49.3M shares | – | Nov 26, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Provectus Biopharmaceuticals, Inc. shares.
No Form 144 notices for Provectus Biopharmaceuticals, Inc. are on file.